The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | The current role of SCT in LBCL in the era of novel therapies: identifying patients who may benefit
In this video, Daniel Landsburg, MD, University of Pennsylvania, Philadelphia, PA, briefly comments on the evolving role of stem cell transplantion (SCT) in the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients, noting that novel therapies such as CAR T-cells and bispecific antibodies are increasingly replacing SCT as a treatment option. However, he suggests that SCT may still be beneficial for a small proportion of patients with favorable molecular risk features or those who relapse late after initial therapy, offering a potentially higher cure rate and prolonged progression-free survival (PFS). This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So stem cell transplant continues to fall more and more out of favor as a therapy for relapsed large B-cell lymphoma patients, obviously with CAR T-cells and that therapy being approved in the second line, and now bispecific antibody therapies that are approved in the third line and available in the United States in the second line. And I do think there might still be some patients who could be candidates for stem cell transplant, but it might be hard to identify them...
So stem cell transplant continues to fall more and more out of favor as a therapy for relapsed large B-cell lymphoma patients, obviously with CAR T-cells and that therapy being approved in the second line, and now bispecific antibody therapies that are approved in the third line and available in the United States in the second line. And I do think there might still be some patients who could be candidates for stem cell transplant, but it might be hard to identify them. Those patients may have more favorable molecular risk features. We do know that patients who relapse late after a year of the completion of their initial therapy may be good candidates as well. So I think there’s a small proportion of patients who still may benefit from stem cell transplant over these newer therapies. And we do know, however, that stem cell transplant provides a very, very long progression-free survival and cure and potentially a higher rate than some of these other therapies. So I do think it’s worth continuing to investigate which patients may respond well to stem cell transplant because for those who do well with it, it’s a very, very effective therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
